Accumulation of risk factors increases risk of thromboembolic events in patients with nonvalvular atrial fibrillation

Circulation Journal

Volumn 70, Issue 6, 2006, Pages 651-656

  Inoue, Hiroshi ^a   Nozawa, Takashi ^a   Hirai, Tadakazu ^a   Iwasa, Atsushi ^b   Okumura, Ken ^b   Lee, Jong Dae ^c   Shimizu, Akihiko ^d   Hayano, Motonobu ^e   Yano, Katsusuke ^e  

^a UNIVERSITY OF TOYAMA   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c UNIVERSITY OF FUKUI   (Japan)

^d YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e NAGASAKI UNIVERSITY   (Japan)

Author keywords

Anticoagulation; Atrial fibrillation; INR level; Thromboembolic events

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; TICLOPIDINE; WARFARIN;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; SCORING SYSTEM; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIOMYOPATHIES; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; JAPAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; THROMBOEMBOLISM;

EID: 33744492398     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.70.651     Document Type: Article

References (15)

1. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457.
2. Fuster V, Rydén LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation 2001; 104: 2118-2150.
3. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the national registry of atrial fibrillation. JAMA 2001; 285: 2864-2870.
4. Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med 2001; 40: 1183-1188.
5. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al for the Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834-1840.
6. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
7. Nozawa T, Inoue H, Iwasa A, Okumura K, Lee JD, Shimizu A, et al. Effects of anticoagulation intensity on hemostatic markers in patients with non-valvular atrial fibrillation. Circ J 2004; 68: 29-34.
8. Nozawa T, Inoue H, Hirai T, Iwasa A, Okumura K, Lee JD, et al. D-dimer level influences thromboembolic events in patients with atrial fibrillation. Int J Cardiol 2005 (e-pub).
9. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: 1. Clinical features of patients at risk. Ann Intern Med 1992; 116: 1-5.
10. Inoue H, Nozawa T, Okumura K, Lee JD, Shimizu A, Yano K. Prothrombotic activity is increased in patients with nonvalvular atrial fibrillation and risk factors for embolism. Chest 2004; 126: 687-692.
11. Inoue H, Nozawa T, Okumura K, Iwasa A, Lee JD, Shimizu A, et al. Attitudes of Japanese cardiologists toward anticoagulation for nonvalvular atrial fibrillation and reasons for its underuse. Circ J 2004; 68: 417-421.
12. Furlan AJ, Craciun AR, Raju NR, Hart N. Cerebrovascular complications associated with idiopathic hypertrophic subaortic stenosis. Stroke 1984; 15: 282-284.
13. Yamamoto K, Ikeda U, Furuhashi K, Irokawa M, Miyamoto T, Shimada K. The coagulation system is activated in idiopathic cardiomyopathy. J Am Coll Cardiol 1995; 25: 1634-1649.
14. Nozawa T, Asanoi H, Inoue H, TOWARD Investigators. Instability of anticoagulation intensity contributes to occurrence of ischemic stroke in patients with non-rheumatic atrial fibrillation. Jpn Circ J 2001; 65: 404-408.
15. Sherman DG, Kim SG, Boop BS, Corley SD, DiMarco JP, Hart RG, et al for the National Heart, Lung, and Blood Institute AFFIRM Investigators. Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study. Arch Intern Med 2005; 165: 1185-1191.